Issue Date: October 22, 2012
Merck Seeks Antiviral With AiCuris …
Merck & Co. has licensed a portfolio of drug candidates targeting human cytomegalovirus (HCMV) from Germany’s AiCuris, a 2006 spin-off from Bayer HealthCare. Merck will pay AiCuris $144 million up front and up to $436 million in potential milestones. It will also cover development costs. Included in the agreement is letermovir, an oral, late-stage antiviral candidate being tested against HCMV infections in transplant recipients. The agreement marks the first development deal emerging from AiCuris’ anti-infective drug R&D programs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society